Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Operating Expenses: 2015-2024

Historic Other Operating Expenses for Insight Molecular Diagnostics (IMDX) over the last 9 years, with Dec 2024 value amounting to $41.7 million.

  • Insight Molecular Diagnostics' Other Operating Expenses fell 41.78% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 68.16%. This contributed to the annual value of $41.7 million for FY2024, which is 722.75% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Other Operating Expenses stood at $41.7 million for FY2024, which was up 722.75% from $5.1 million recorded in FY2023.
  • In the past 5 years, Insight Molecular Diagnostics' Other Operating Expenses ranged from a high of $41.7 million in FY2024 and a low of -$11.2 million during FY2022.
  • In the last 3 years, Insight Molecular Diagnostics' Other Operating Expenses had a median value of $5.1 million in 2023 and averaged $11.9 million.
  • In the last 5 years, Insight Molecular Diagnostics' Other Operating Expenses soared by 1,019.89% in 2021 and then crashed by 140.27% in 2022.
  • Insight Molecular Diagnostics' Other Operating Expenses (Yearly) stood at $2.5 million in 2020, then skyrocketed by 1,019.89% to $27.8 million in 2021, then slumped by 140.27% to -$11.2 million in 2022, then spiked by 145.28% to $5.1 million in 2023, then surged by 722.75% to $41.7 million in 2024.